Navigation Links
First Complete Career Service for Life-Science Professionals
Date:2/25/2008

Online Career Recommendations Customized For Each Individual

SANTA CRUZ, Calif., Feb. 25 /PRNewswire/ -- Bio Career Center (http://www.BioCareerCenter.com), an online job board and careers tool site for life-science professionals, and AdvisorTeam (http://www.AdvisorTeam.com), an innovative leader in online personality assessments, have joined forces to provide a new, focused program for a specialized group of skilled workers. The two companies today unveiled a personality-based test which produces customized career recommendations for those in clinical and life-science fields.

"As Bio Career Center is the first and only career service dedicated to expanding professional options for life-science Ph.D.s and M.D.s, it's a natural fit for AdvisorTeam's customized personality tools which can target specific career paths for this challenging industry," said Kip Parent, CEO of AdvisorTeam.

Bio Career Center features a jobs board that gathers the life-sciences postgraduate and clinical communities of each member school into one place. Bio Career Center's staff works with employers and provides deep, rich content focused on all of the alternatives that life-sciences Ph.D.s and M.D.s have before them. The company also works with higher learning institutions including: University of California, Berkeley, Caltech, Scripps Institute, Stanford, University of California at San Francisco, University of Pennsylvania and University of Washington. Last month, Bio Career Center added Emory University, University of Colorado Denver and Vanderbilt University to its fold, rounding out an already elite consortium of higher education institutions. This experience is combined with AdvisorTeam's professionals who have created an online enabled technology to help people and organizations better understand themselves and others.

"There are load
'/>"/>

SOURCE Bio Career Center
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
2. Biopure Announces 2008 First Quarter Financial Results
3. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
4. European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions
5. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
6. Biodel Inc. Reports First Quarter Fiscal Year 2008 Financial Results
7. Martek to Announce First Quarter 2008 Results on March 5, 2008
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
10. Elekta Announces First Volumetric Modulated Arc Therapy Cancer Treatment at Royal Marsden Hospital
11. Biodel Inc. to Announce First Quarter Fiscal Year 2008 Financial Results on February 14, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):The impact of the diffusion of maize to the Southwestern United States 2Small addition to cancer drug may make big difference 2Small addition to cancer drug may make big difference 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 4Separation Anxiety Canine Style 57630 1Separation Anxiety Canine Style 57630 2Separation Anxiety Canine Style 57630 3Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next Generation Everolimus Stent 14141 1Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next Generation Everolimus Stent 14141 2Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next Generation Everolimus Stent 14141 3Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next Generation Everolimus Stent 14141 4NewCardio Completes 242 9 Million Private Placement 57625 1NewCardio Completes 242 9 Million Private Placement 57625 2NewCardio Completes 242 9 Million Private Placement 57625 3NewCardio Completes 242 9 Million Private Placement 57625 4